Pediatrix Medical (MD) Cash & Equivalents (2009 - 2026)

Pediatrix Medical (MD) has 18 years of Cash & Equivalents data on file, last reported at $205.8 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $205.8 million, up 107.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $205.8 million (up 107.9% YoY), and the FY2025 annual result was $375.2 million, up 63.19% from the prior year.
• Cash & Equivalents retreated to $205.8 million in Q1 2026 per MD's latest filing, from $375.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $375.2 million in Q4 2025 and troughed at $5.8 million in Q2 2023.
• A 5-year average of $103.1 million and a median of $21.2 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents plunged 97.58% in 2022, then surged 1137.53% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $9.8 million in 2022, then jumped by 645.7% to $73.3 million in 2023, then surged by 213.88% to $229.9 million in 2024, then soared by 63.19% to $375.2 million in 2025, then slumped by 45.16% to $205.8 million in 2026.
• Business Quant data shows MD's Cash & Equivalents at $205.8 million in Q1 2026, $375.2 million in Q4 2025, and $340.1 million in Q3 2025.